Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MIRM
MIRUM PHARMACEUTICALS, INC.
NASDAQ
$100.90
▲ UP 0.27% (0.27)

KEY STATISTICS

Market Cap$6.15 B
52w High$130.00
52w Low$63.23
Dividend Yield—
Frequency—
P/E-6.93
Volume343.86K
Shares Out.60.98M

COMPANY

LEADERSHIP

Christopher Peetz
CHIEF EXECUTIVE
Christopher Peetz

COMPENSATION 2026

Salary$755,000
Stock Awards$3,683,904
Incentive Plan Pay$1,057,000
All Other Comp.$14,000
Total$10,441,224

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 18, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
433

PRICE TARGET

Target High$165.00
Target Low$123.00
Target Median$137.50
Target Consensus$140.20

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$178.06M
NOV
3
TUE

PRICE

$100.90 ▲ UP 0.27% (+$0.27)
$100$101$1029:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM100.90

About Mirum Pharmaceuticals, Inc.

https://www.mirumpharma.com ↗

Mirum Pharmaceuticals, founded in 2018 in Foster City, CA, develops and commercializes novel therapies for rare diseases, including LIVMARLI for cholestasis and Alagille syndrome, and Volixibat for intrahepatic cholestasis of pregnancy and primary...

INDUSTRY

Biotechnology

A PRODUCT MIRUM PHARMACEUTICALS, INC. IS KNOWN FOR

LIVMARLI® (maralixibat)
LIVMARLI® (maralixibat)

Mirum's once-daily IBAT inhibitor treats cholestatic pruritus in Alagille syndrome and PFIC, representing a key commercial product that advances rare liver disease therapy and drives the company's revenue.

COMPETITORS

COMPETITOR
ALNY COMPARE
GILD COMPARE
RARE COMPARE
TVTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$133.01M $148.93M ▲$159.88M ▲$176.24M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$103.71M $115.38M ▲$127.93M ▲$138.34M ▲
NonUS— — $31.95M $37.91M ▲
Rest Of World$29.3M — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
162
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 1.7M
XSU.TO
0.15% · 1.2M
XBI
0.99% · 1.1M
SCHA
0.10% · 228.8K
FESM
0.19% · 124.6K
TMSL
0.19% · 58.2K
LF
LFSC
4.38% · 55.6K
FTXH
0.47% · 50.5K
XRSG.L
0.15% · 41.8K
LABU
0.66% · 37.6K
RSSL
0.15% · 22.8K
GSSC
0.20% · 21.8K
FSCC
0.36% · 15.1K
BBP
1.24% · 14.7K
PRFZ
0.05% · 13.4K
BBSC
0.17% · 12.7K
EZM
0.09% · 8.8K
BIGT.L
2.66% · 6.5K
AI
AIMS
0.44% · 3.9K
EH
EHLS
0.39% · 2.2K
BIB
0.21% · 2.2K
STXK
0.25% · 2.1K
BKSE
0.24% · 2.1K
RFLR
0.20% · 1.9K
ESSC
0.36% · 1.3K
TILT
0.01% · 1.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.75%
HOLDERS
435
TOP 12 OF 435 · RANKED BY POSITION SIZE
Frazier Life Sciences Management, L.P.
7.7M sh · $899.06M
Janus Henderson Group Plc
6.8M sh · $627.3M
Blackrock, Inc.
4.4M sh · $513.94M
Fmr LLC
3.7M sh · $429.68M
Blackrock Inc.
3.2M sh · $110.71M
Price T Rowe Associates Inc /Md/
2.7M sh · $310.89M
Vanguard Group Inc
2.6M sh · $205.07M
Eventide Asset Management, LLC
2.5M sh · $184.92M
State Street Corp
2.2M sh · $254.12M
Bvf Inc/Il
1.6M sh · $146.4M
William Blair Investment Management, LLC
1.4M sh · $164.45M
Geode Capital Management, LLC
1.4M sh · $163.21M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: SVP, GLOBAL CONTROLLER
Howe Jolanda
Sale · 658 shares
2026-09-02
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Peetz Christopher
Purchase · 30.0K shares
2026-09-01
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Peetz Christopher
Sale · 8.3K shares
2026-09-01
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Peetz Christopher
Sale · 21.7K shares
2026-09-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 4
BUY 3
OVERWEIGHT 3
MARKET OUTPERFORM 1
11 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM HC Wainwright & Co. BUY TD Cowen BUY RBC Capital OUTPERFORM JP Morgan OVERWEIGHT Morgan Stanley OVERWEIGHT Baird OUTPERFORM Evercore ISI Group OUTPERFORM

SECTORS PEERS

PEERPRICE
PRAX$353.02COMPARE
BLTE$186.15COMPARE
TVTX$65.61COMPARE
LGND$287.72COMPARE
ACAD$28.02COMPARE
DYN$24.37COMPARE
TLX$11.90COMPARE
ADMA$9.57COMPARE